Raynaud syndrome with / without systemic sclerosis
Conditions
Interventions
Trade Name: Ilomedin
Product Name: Ilomedin
Product Code: 1-22460
Pharmaceutical Form: Intravenous infusion
Pharmaceutical form of the placebo: Intravenous infusion
Route of administration of the plac
Sponsors
ao. Univ. Prof. Dr. Elisabeth Aberer
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients with Raynaud syndrome with / without scleroderma, Iloprost treatment since >1 month Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range
Exclusion criteria
Exclusion criteria: Abnormal hemostasis, diabetes, pregnancy, breast feeding, coronary heart disease
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Main Objective: To compare the action of Iloprost on the number, severity and duration of Raynaud attacks in comparison to placebo in patients with Raynaud syndrome with / without scleroderma. ;Secondary Objective: Measuring skin temperature before and after infusion of iloprost or placebo.;Primary end point(s): Number, duration and severity of Raynaud attacks after treatment with Iloprost or placebo for 5 months. | — |
Countries
Austria
Outcome results
None listed